On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

There's so much growth on the horizon for Eli Lilly, and with the stock's payout ratio still at a fairly modest 54% of earnings, there is more room for the business to continue making generous ...

Eli Lilly's (LLY) Potential New Products Key to Growth August 15, 2022 — 10:15 am EDT Written by Zacks Equity Research for Zacks -> ...

Eli Lilly's competitive position in the obesity market is discussed in today's article along with the potential for growth acceleration in 2025 and 2026 versus current expectations for moderating ...

Eli Lilly didn't generate much growth last year, but its future looks promising. Mounjaro has the potential to be a game-changing product for the business. It could significantly propel the ...

Eli Lilly Earnings: Solid Results and Strong Mounjaro Data Set Up Robust Long-Term Growth Potential Despite potential for Lilly’s growth, we remain concerned about the stock’s valuation.

Eli Lilly (LLY-3.41%) is the ... The company's diverse pipeline underscores many growth opportunities. Eli Lilly has dozens of projects in its pipeline, ... but that has even more potential as a ...